Human Pathology
Volume 41, Issue 2 , Pages 155-162 , February 2010

Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features

  • Kurt B. Hodges, MD, MBA

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • ,
  • Antonio Lopez-Beltran, MD, PhD

      Affiliations

    • Department of Pathology, Cordoba University, E-14004 Cordoba, Spain
    • ,
  • Darrell D. Davidson, MD, PhD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • ,
  • Rodolfo Montironi, MD

      Affiliations

    • Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region (Ancona), United Hospitals, 60020 Ancona, Italy
    • ,
  • Liang Cheng, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Received 28 May 2009 ,Revised 2 July 2009 ,Accepted 9 July 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  2. Cheng L, Lopez-Beltran A, MacLennan GT, Montironi R, Bostwick DG. Neoplasms of the urinary bladder. In:  Bostwick DG,  Cheng L editor. Urologic surgical pathology. 2nd ed.. Philadelphia: Elsevier/Mosby; 2008;p. 259–352
  3. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435–1448
  4. Eble JN, Sauter G, Epstein JI, Sesterhenn IAE. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004;
  5. Lopez-Beltran A, Cheng L, Andersson L, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch. 2002;440:3–11
  6. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85:2469–2474
  7. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25:356–362
  8. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L. Morphological classification and definition of the benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology. 2008;53:621–633
  9. Emerson RE, Cheng L. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol. 2005;27:301–316
  10. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000;13:1315–1323
  11. Requena MJ, Alvarez-Kindelan J, Blanca A. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol. 2007;29:380–382
  12. Brunner A, Schönhuber G, Waldner M, Schaefer G, Mikuz G, Verdorfer I. Chromosomal aberrations in urothelial carcinoma of the bladder and the World Health Organization 2004 grading system. Anal Quant Cytol Histol. 2008;30:297–305
  13. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25:1074–1078
  14. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol. 1999;154:721–727
  15. Obermann EC, Junker K, Stoehr R, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol. 2003;199:50–57
  16. van Oers JM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer. 2006;119:1212–1215
  17. Majewski T, Lee S, Jeong J, et al. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008;88:694–721
  18. Cheng L, Bostwick DG. Overdiagnosis of bladder carcinoma. Anal Quant Cytol Histol. 2008;30:261–264
  19. Sarma KP. Genesis of papillary tumours: histological and microangiographic study. Br J Urol. 1981;53:228–236
  20. Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol. 1996;20:1481–1488
  21. Swierczynski SL, Epstein JI. Prognostic significance of atypical papillary urothelial hyperplasia. Hum Pathol. 2002;33:512–517
  22. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer. 2000;88:625–631
  23. Epstein JL, Amin MB, Reuter VR, Mostofi FK. The bladder consensus conference committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435–1438
  24. Lopez-Beltran A, Luque RJ, Mazzuchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol. 2002;55:641–647
  25. Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005;55:248–254
  26. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L. 2004 World Health Organization classification of the noninvasive urothelial neoplasms: inherent problems and clinical reflections. Eur Urol. 2009;8(Suppl):453–457
  27. Jones TD, Cheng L. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol. 2006;175:1995–2003
  28. Maclennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol. 2007;51:889–898
  29. Grignon DJ. The current classification of urothelial neoplasms. Mod Pathol. 2009;22(Suppl2):S60–90
  30. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009;22(Suppl2):S70–95
  31. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol. 1999;23:443–447
  32. Chandramouly G, Abad PC, Knowles DW, Lelievre SA. The control of tissue architecture over nuclear organization is crucial for epithelial cell fate. J Cell Sci. 2007;120:1596–1606
  33. Shirai T, Fukushima S, Hirose M, Ohshima M, Ito N. Epithelail lesions of the urinary bladder in 313 autopsy cases. Jpn J Cancer Res. 1987;78:1073–1080
  34. Zuk R, Rogers H, Martin J, Baithun S. Clinicopathological importance of primary dsyplasia of bladder. J Clin Pathol. 1988;41:1277–1280
  35. Baithun S, Rogers H, Martin J, Zuk R, Blandy J. Primary dysplasia of bladder. Lancet. 1988;1(8583):483
  36. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996;78:870–875
  37. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784–788
  38. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713–725
  39. Baithun SI, Naase M, Blanes A, Diaz-Cano SJ. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch. 2001;438:289–297
  40. Baud E, Catilina P, Boiteux JP, Bignon YJ. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion. Int J Cancer. 1998;77:821–824
  41. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000;19:3309–3320
  42. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24:5218–5225
  43. Chern HD, Becich MJ, Persad RA, et al. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins. J Urol. 1996;156:1846–1849
  44. Fadl-Elmula I, Gorunova L, Mandahl N, et al. Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding. Br J Cancer. 1999;81:6–12
  45. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet. 1993;342:1087–1088
  46. Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002;101:1–6
  47. Yoshimura I, Kudoh J, Saito S, Tazaki H, Shimizu N. p53 gene mutation in recurrent superficial bladder cancer. J Urol. 1995;153:1711–1715
  48. Hafner C, Knuechel R, Zanardo L, et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 2001;20:4910–4915
  49. Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11:6512–6519
  50. Hartmann A, Rosner U, Schlake G, et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest. 2000;80:709–718
  51. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62:809–818
  52. Steidl C, Simon R, Burger H, et al. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol. 2002;198:115–120
  53. Lee S, Jeong J, Majewski T, et al. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci USA. 2007;104:13732–13737
  54. Tuziak T, Jeong J, Majewski T, et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest. 2005;85:689–701
  55. Lopez-Beltran A, Alvarez-Kindelan J, Luque RJ, et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol. 2008;215:263–272

PII: S0046-8177(09)00250-0

doi: 10.1016/j.humpath.2009.07.002

Human Pathology
Volume 41, Issue 2 , Pages 155-162 , February 2010

Article Tools

* Image Usage & Resolution